BOULDER — Biodesix Inc., a Boulder-based developer and manufacturer of blood-test kits, has signed a deal to have its blood tests for patients with advanced lung cancer marketed and distributed in Israel.
Tel Aviv-based Progenetics Ltd. will handle Biodesix’s kits for its GeneStrat and VeriStrat liquid biopsy tests. Financial terms of the deal were not disclosed.
This is the second international agreement that Biodesix has announced this year; the company entered into a collaboration with Beijing-based Bioyong Industries in January.
These tests provide physicians with genomic information within 72 hours that can be used select therapies and accelerate treatment, much sooner than the 10 days to two weeks average turnaround time for tissue-based testing, said David Brunel, Biodesix’s chief executive.